$-0.14 EPS Expected for Can-Fite BioPharma Ltd. (CANF)

March 15, 2018 - By Vivian Park

 $ 0.14 EPS Expected for Can Fite BioPharma Ltd. (CANF)

Analysts expect Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) to report $-0.14 EPS on March, 30.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.14 EPS. After having $-0.04 EPS previously, Can-Fite BioPharma Ltd.’s analysts see 250.00 % EPS growth. The stock decreased 3.77% or $0.06 during the last trading session, reaching $1.53. About 78,407 shares traded. Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) has declined 27.09% since March 15, 2017 and is downtrending. It has underperformed by 43.79% the S&P500.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company has market cap of $29.43 million. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It currently has negative earnings. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.

More important recent Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) news were published by: Quotes.Wsj.com which released: “News Can-Fite Biopharma Ltd. ADRCANF” on November 19, 2013, also Seekingalpha.com published article titled: “Can-Fite’s Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III …”, Marketwatch.com published: “Can-Fite Biopharma Ltd. ADR” on July 05, 2016. More interesting news about Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) was released by: Investorplace.com and their article: “CANF: Take Multiple Shots on Goal With Can-Fite BioPharma” with publication date: March 18, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: